Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Revista Colombiana de Reumatología
Print version ISSN 0121-8123
Abstract
PORTA, Sobrina et al. Systemic lupus erythematosus diagnosed during hospitalization: Greater baseline disease activity, short-term damage, and death. Rev.Colomb.Reumatol. [online]. 2022, vol.29, n.2, pp.101-106. Epub Feb 21, 2023. ISSN 0121-8123. https://doi.org/10.1016/j.rcreu.2021.01.010.
Objectives:
To analyze initial and follow-up features of patients with systemic lupus erythematosus (SLE) diagnosed during hospitalization.
Methods:
Retrospective analysis of medical records: two groups were studied, a) SLE diagnosed during hospitalization (SLEin), b) SLE diagnosed on an outpatient basis (SLEout). Results: 123 patients were assessed, 87% female, mean age at diagnosis was 34 years and 45 (37%) of them were SLEin. Patients in the SLEin group had a median of 144 days from the onset of symptoms to diagnosis of SLE vs. 287 days in the SLEout group (p = 0.04). Initially, SLEin had an average SLEDAI of 10 vs. 8 in SLEout (p = 0.004) and anti-dsDNA was positive in 71% vs. 53% in SLEout (p = 0.07). Within the first 6 months, the average cumulative glucocorticoid dose was 6493 mg in SLEin patients vs. 3563 mg in SLEout (p < 0.001) and immunosuppressant usage was higher in SLEin: 62% vs. 26% in SLEout (p<0.001). Within the first year, SLEin's kidney biopsies showed lupus nephritis III or IV in 31% vs. 12% in SLEout (p = 0.003, log-rank test). Within the first 2 years, 6 SLEin patients died vs. 1 SLEout patient (p = 0.02) and SLEin patients had more damage as measured by SLICC/ACR Damage Index (median 0, range 25%-75% 0-1 vs. median 0, range 25%-75% 0-0 in SLEout; p = 0.04).
Conclusions:
SLEin are initially more active, require higher doses of glucocorticoids and immunosuppressants, have more significant kidney involvement, and present more damage and greater mortality in the short term.
Keywords : Systemic lupus erythematosus; Hospitalizations; SLEDAI; Use of glucocorticoids; Cumulative damage; Mortality.